Cargando…
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
PURPOSE: We sought to identify features of patients with advanced non–small cell lung cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors (ICI), and how these might differ from features predictive of short-term response (STR). EXPERIMENTAL DESIGN: We performed a multi...
Autores principales: | Thummalapalli, Rohit, Ricciuti, Biagio, Bandlamudi, Chaitanya, Muldoon, Daniel, Rizvi, Hira, Elkrief, Arielle, Luo, Jia, Alessi, Joao V., Pecci, Federica, Lamberti, Giuseppe, Di Federico, Alessandro, Hong, Lingzhi, Zhang, Jianjun, Heymach, John V., Gibbons, Don L., Plodkowski, Andrew J., Ravichandran, Vignesh, Donoghue, Mark T.A., Vanderbilt, Chad, Ladanyi, Marc, Rudin, Charles M., Kris, Mark G., Riely, Gregory J., Chaft, Jamie E., Hellmann, Matthew D., Vokes, Natalie I., Awad, Mark M., Schoenfeld, Adam J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618656/ https://www.ncbi.nlm.nih.gov/pubmed/37432985 http://dx.doi.org/10.1158/1078-0432.CCR-23-1207 |
Ejemplares similares
-
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023) -
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023) -
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023) -
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023) -
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
por: Alessi, Joao V, et al.
Publicado: (2020)